On the prevention and therapy of prostate cancer by androgen administration

Cancer Research

Volumn 59, Issue 17, 1999, Pages 4161-4164

  Prehn, Richmond T ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN THERAPY; CANCER GROWTH; CARCINOGENESIS; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; REVIEW;

ANDROGENS; HUMANS; MALE; PHENOTYPE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0033199134     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Ross, R. K., Pike, M. C., Coetzee, G. A., Reichardt, J. K. V., Mimi, C. Y., Feigelson, H., Stanczyk, F. Z., Kolonel, L. N., and Henderson, B. E. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res., 58: 4497-4504, 1998.
2. Pollard, M. Lobund-Wistar rat model of prostate cancer in man. Prostate, 37: 1-4, 1998.
3. Noble, R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 37: 1929-1933, 1977.
4. Carter, H. B., Pearson, J. D., Metter, E. J., Chan, D. W., Andres, R., Fozard, J. L., Rosner, W., and Walsh, P. C. Longitudinal evaluation of serum androgen levels in men with and without prostate cancer. Prostate, 27: 25-31, 1995.
5. Harper, M. E., Pierrepoint, C. G., and Griffiths, K. Carcinoma of the prostate: relationship of pre-treatment hormone levels to survival. Eur. J. Cancer Clin. Oncol., 20: 477-482, 1984.
6. Meikle, A. W., and Stanish, W. M. Familial prostatic cancer risk and low testosterone. J. Clin. Endocrinol. Metab., 54: 1104-1108, 1982.
7. Gann, P. H., Hennekens, C. H., Ma, J., Longcope, C., and Stampfer, M. J. Prospective study of the sex hormone levels and risk of prostate cancer. J. Natl. Cancer Inst., 88: 1118-1126, 1996.
8. Davies, P., and Eaton, C. L. Regulation of prostate growth. J. Endocrinol., 131: 5-16, 1991.
9. Bruchovsky, N., Lesser, B., Van Dorn, E., and Craven, S. Hormonal effects on cell proliferation in rat prostate. Vitam. Horm., 33: 61-102, 1975.
10. Cook, P. J., Doll, R., and Fellingham, S. A. A mathematical model for the age distribution of cancer in man. Int. J. Cancer, 4: 93-112, 1969.
11. Renan, M. J. How many mutations are required for tumorigenesis? Implications from human cancer data. Mol. Carcinog., 7: 139-146, 1993.
12. Dai, W. S., Kuller, L. H., LaPorte, R. E., Gutai, J. P., Falvo-Gerard, L., and Caggiula, A. The epidemiology of plasma testosterone levels in middle-aged men. Am. J. Epidemiol., 114: 804-816, 1981.
13. Sternbach, H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am. J. Psychiatry, 155: 1310-1318, 1998.
14. Morley, J. E., Kaiser, F. E., Perry, H. M. I., Patrick, P., Morley, P. M., Stauber, P. M., Vellas, B., Baumgartner, R. N., and Garry, P. J. Longitudinal changes in testosterone, luteinizing hormone, and follicle stimulating hormone in healthy older men. Metabolism, 46: 410-413, 1997.
15. Daniell, H. W. A worse prognosis for men with testicular atrophy at therapeutic orchiectomy for prostate carcinoma. Cancer (Phila.), 83: 1170-1173, 1998.
16. Farber, E. Foundations in cancer research. The step by step development of epithelial cancer: from phenotype to genotype. Adv. Cancer Res., 70: 21-48, 1996.
17. Farber, E. Investigative toxicologic pathology in safety assessment: a commentary. Toxicol. Pathol., 25: 660-661, 1997.
18. Franks, L. M. Atrophy and hyperplasia in the prostate proper. J. Pathol. Bacteriol., 68: 617-621, 1954.
19. Rubin, H. Cancer and complexity: correlations and complementarity. J. Surg. Oncol., 69: 4-8, 1998.
20. Farber, M., and Rubin, H. Cellular adaptation in the origin and development of cancer. Cancer Res., 51: 2751-2761, 1991.
21. Prehn, R. T. Cancers beget mutations versus mutations beget cancers. Cancer Res., 54: 5296-5300, 1994.
22. Loeb, L. A. Cancer cells exhibit a mutator phenotype. Adv. Cancer Res., 72: 25-56, 1998.
23. Prehn, R. T. The inhibition of tumor growth by tumor mass. Cancer Res., 51: 2-4, 1991.
24. Naora, H., Seno, S., and Naora, H. Regulation of tumor growth as a "total mass" in mice: apoptosis as a major mechanism in altering growth rates of single and multiple coexisting tumor nodules. Pathol. Int., 48: 730-738, 1998.
25. Sonnenschein, C., Olea, N., Pasanen, M., and Soto, A. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res., 49: 3474-3481, 1989.
26. Geck, P., Szelei, J., Jimenez, J., Lin, T. M., Sonnenschein, C., and Soto, A. M. Expression of novel genes linked to the androgen-induced proliferative shutoff in prostate cancer cells. J. Steroid Biochem. Mol. Biol., 63: 211-218, 1997.
27. Szelei, J., Jimenez, J., Soto, A. M., Luizzi, M. F., and Sonnenschein, C. Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology, 138: 1406-1412, 1997.
28. Yuan, S. X., Trachtenberg, J., Mills, G. B., Brown, T. J., and Xu, F. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res., 53: 1304-1311, 1993.
29. Joly-Pharaboz, M. O., Soave, M. C., Nicolas, B., Mebarki, F., and Renaud, M. Androgens inhibit the proliferation of a variant of the human prostate cancer cell line LNCaP. J. Steroid Biochem. Mol. Biol., 55: 67-76, 1995.
30. Story, M. T. Positive and negative modulators of prostate cell proliferation. Biomed. Pharmacother., 48: (Suppl. 1): S35-S41, 1994.
31. Zhau, H. Y. E., Chang, S. M., Chen, B. Q., Wang, Y. L., Zhang, H. Q., Kao, C. H., Sang, Q. X. A., Pathak, S. J., and Chung, L. W. K. Androgen-repressed phenotype in human prostate cancer. Proc. Natl. Acad. Sci. USA, 93: 15152-15157, 1996.
32. López-Otín, C. and Diamandis, E. P. Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocrinol. Rev., 19: 365-396, 1998.
33. Fowler, J. E., and Whitmore, W. F. The response of the metastatic adenocarcinoma of the prostate to exogenous testosterone. J. Urol., 126: 372-375, 1981.
34. Manni, A., Bartholomew, M., Caplan, R., Boucher, A., Santen, R., Lipton, A., Harvey, H., Simmonds, M., White-Hershey, D., and Gordon, R. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J. Clin. Oncol., 6: 1456-1466, 1988.
35. Prout, G. R. J., and Brewer, W. R. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer (Phila.), 20: 1871-1878, 1967.
36. Trunnell, J. D., and Duffy, B. J., Jr. The influence of certain steroids on the behavior of human prostate cancer. Trans. N. Y. Acad. Sci. II, 12: 238-241, 1950.
37. Brendler, H., Lowry, O., and Brock, M. Further investigation of hormonal relationships. Arch. Surg., 61: 433-440, 1950.
38. Pearson, O. H. Discussion of Dr. Huggins' paper: "Control of cancers of man by endocrinological methods." Cancer Res., 17: 473-479, 1957.
39. Morales, A., Connolly, J., Burr, R., and Bruce, A. The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate. Can. Med. Assoc. J., 103: 372-373, 1970.
40. Umekita, Y., Hiipakka, R. A., Kokontis, J. M., and Liao, S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc. Natl. Acad. Sci. USA, 93: 11802-11807, 1996.
41. Dupont, A., Gomez, J. L., Cusan, L., Koutsilieris, M., and Labrie, F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908-913, 1993.
42. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., and Klocker, H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, kertinocyte growth factor, and epidermal growth factor. Cancer Res., 54: 5474-5478, 1994.
43. Shimizu, H., Ross, R. K., and Bernstein, L. Possible underestimation of the incidence rate of prostate cancer in Japan. Jpn. J. Cancer Res., 82: 483-485, 1991.
44. Robbins, A. S., Whittemore, A. S., and Vandeneeden, S. K. Race, prostate cancer survival, and membership in a large health maintenance organization. J. Natl. Cancer Inst., 90: 986-990, 1998.